AASM, Events

SLEEP 2026: What Stood Out From Baltimore

The 40th annual SLEEP meeting drew its usual crowd of clinicians, researchers, technologists, and industry representatives to Baltimore — but this year’s meeting felt different in at least one important way. The pharmaceutical presence on the exhibit floor and in sponsored symposia has grown substantially over the past decade, and […]

Dental Sleep Medicine, Obstructive Sleep Apnea, Telemedicine

ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA

ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]

Sleep Pharmaceuticals

Jazz Delivers Extensive Data at SLEEP 2026, Real-World Impact of Xywav on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]

Research/Studies

The Syn-Sleep Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder

On Wednesday morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]